VIVUS Inc. is a developer of next generation of clinical therapies that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on VVUS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that VIVUS could be a solid choice for investors.

Current Quarter Estimates for VVUS

In the past 30 days, VIVUS’ trend has been pretty favorable, with estimates narrowing from a loss of 25 cents a share 30 days ago, to a loss of 20 cents today, a move of 20 %.

Current Year Estimates for VVUS

Meanwhile, VIVUS’ current year figures are also looking quite promising. The consensus estimate trend has seen a boost for this time frame, narrowing from a loss of 74 cents per share 30 days ago to a loss of 63 cents per share today, an increase of 14.9%.

VIVUS INC Price and Consensus

VIVUS INC Price and Consensus | VIVUS INC Quote

Bottom Line

The stock has also started to move higher lately, adding 5.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>